Ovarian Cancer Clinical Trials in Boston

Showing 41-60 of 216 trials

ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)

NCT04044859

This study will investigate the safety and tolerability of ADP-A2M4CD8 T-cell therapy in subjects who have the appropriate human leukocyte antigen (HLA) and MAGE-A4 tumor antigen. Tumor indications include endometrial, esophageal, esophagogastric junction (EGJ), gastric, head and neck, melanoma, non-small cell lung (NSCLC), ovarian or urothelial cancer.

Endometrial CancerEsophageal CancerEsophagogastric Junction (EGJ)+6 more

USWM CT, LLC120 participantsStarted Aug 2019

Orlando, Florida, United States • Boston, Massachusetts, United States • St Louis, Missouri, United States +14 more locations

TERMINATEDPhase 1< 1 mile

A Study of PHN-010 in Patients With Advanced Solid Tumors

NCT06457997

This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-010, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.

Lung CancerColon CancerEndometrial Cancer+4 more

Pheon Therapeutics26 participantsStarted Jul 2024

Orlando, Florida, United States • Boston, Massachusetts, United States • New York, New York, United States +5 more locations

ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)

A Study of PHN-010 in Patients With Advanced Solid Tumors

Ovarian Cancer Trials in Other Cities

Nirogacestat in Ovarian Granulosa Cell Tumors

Zafirlukast in Treatment of Marker Relapsed Ovarian Cancer

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

A Study of PF-06873600 in People With Cancer

A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study

Study of AVZO-021 in Patients With Advanced Solid Tumors

A Study of MGC026 in Participants With Advanced Solid Tumors

BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy

Other Conditions in Boston